Advertisment ACS-IndiaSymposium
Journal of Pharmaceutical Negative Results
  Print this page Email this page Small font sizeDefault font sizeIncrease font size 
Search Article 
Advanced search 
 Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts  

  Table of Contents  
Year : 2018  |  Volume : 9  |  Issue : 1  |  Page : 59  

Adverse events during plateletpheresis donation

Department of Biological Science, Joseph Ayo Babalola University, Ilara-Mokin, Nigeria

Date of Web Publication21-Aug-2018

Correspondence Address:
Viroj Wiwanitkit
Joseph Ayo Babalola University, Ilara-Mokin
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jpnr.JPNR_11_18

Rights and Permissions

How to cite this article:
Wiwanitkit V. Adverse events during plateletpheresis donation. J Pharm Negative Results 2018;9:59

How to cite this URL:
Wiwanitkit V. Adverse events during plateletpheresis donation. J Pharm Negative Results [serial online] 2018 [cited 2020 Jun 6];9:59. Available from:

Dear Sir,

I read the publication on “Underreporting of mild adverse events (AEs) during plateletpheresis donations” with a great interest. Kansay noted that “it is recommended to discuss and create a system of hemovigilance for AE in donations with special consideration to mild AE which are usually underreported.[1]” In clinical practice, the AE might be unexpected but it should not think that it is not preventable. In the present report by Kansay,[1] the incidence was reported. However, it is not clear on how the incidence could be derived. How the AE can be observed and recorded. In details, it is also questionable how to judge an AE is mild or severe. In fact, the monitoring of AE is the basic necessary process in either pharmacological or nonpharmacological management of the patients. The reporting of the event is useful for recording. However, it should not forget a more important necessary process, the planning for preventive and corrective actions. For any centers that severe donations, there must be the quality management system that should described work instructions for the practitioners ranging from pre-, during-and post-donation phase.[2] For any clinical settings, there must be standard procedure for observation and monitoring of AE. There should be standard recording process and/or form. Also, there should be the specific protocol for management of any possible observed AE. For the report by Kansay,[1] the data on these interesting points is lack.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

Kansay S. Underreporting of mild adverse events during plateletpheresis donations. J Pharm Negat Results 2017;8:56-7.  Back to cited text no. 1
Burgstaler EA. Blood component collection by apheresis. J Clin Apher 2006;21:142-51.  Back to cited text no. 2


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded152    
    Comments [Add]    

Recommend this journal